The place of new oral anticoagulants in travel medicine

Travel Medicine and Infectious Disease

Volumn 12, Issue 1, 2014, Pages 7-19

  Ringwald, Juergen ^a   Grauer, Martin ^a   Eckstein, Reinhold ^a   Jelinek, Tomas ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Berlin Centre for Travel and Tropical Medicine   (Germany)

Author keywords

Anticoagulation; Apixaban; Dabigatran; Rivaroxaban; Traveller's thrombosis

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; DABIGATRAN; DABIGATRAN ETEXILATE; DRONEDARONE; FONDAPARINUX; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PHENOBARBITAL; PHENPROCOUMON; PHENYTOIN; POSACONAZOLE; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; TELITHROMYCIN; TICAGRELOR; UNINDEXED DRUG; VERAPAMIL; VORICONAZOLE; WARFARIN;

ANTICOAGULATION; BLEEDING; COMPRESSION STOCKING; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMPORIATRICS; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; HUMAN; INVASIVE PROCEDURE; LABORATORY TEST; LONG TERM CARE; NEEDLE BIOPSY; PATIENT DECISION MAKING; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SYRINGE; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULATION; APIXABAN; DABIGATRAN; RIVAROXABAN; TRAVELLER'S THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; THIOPHENES; TRAVEL MEDICINE;

EID: 84893793691     PISSN: 14778939     EISSN: 18730442     Source Type: Journal    
DOI: 10.1016/j.tmaid.2013.11.005     Document Type: Review

References (59)

1. J. Ringwald, J. Strobel, and R. Eckstein Travel and oral anticoagulation J Travel Med 16 2009 276 283
2. J. Koscielny, J. Beyer-Westendorf, C. von Heymann, J. Braun, R. Klamroth, and E. Lindhoff-Last et al. Risk of bleeding and haemorrhagic complication with rivaroxaban - periprocedural management of haemostasis Hamostaseologie 32 2012 287 293
3. M. Spannagl, R. Bauersachs, E.S. Debus, M. Gawaz, H. Gerlach, and S. Haas et al. Dabigatran therapy - perioperative management and interpretation of coagulation tests Hamostaseologie 32 2012 294 305
4. J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti et al. Pharmacology and management of the vitamin K antagonists: American College of Chest physicians evidence-based clinical practise guidelines (8th edition) Chest 133 6 Suppl. 2008 160S 198S
5. V. Pengo, L. Crippa, A. Falanga, G. Finazzi, F. Marongiu, and G. Palareti et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) Thromb Haemost 106 2011 868 876
6. M.M. Thapar, M. Ashton, N. Lindegardh, Y. Bergqvist, S. Nevelius, and I. Johansson et al. Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis Eur J Clin Pharmacol 58 2002 19 27
7. G. Connolly, and A.C. Spyropoulos Practical issues, limitations, and periprocedural management of the NOAC's J Thromb Thrombolysis 36 2013 212 222
8. W.F. Peacock, M.M. Gearhart, and R.M. Mills Emergency management of bleeding associated with old and new oral anticoagulants Clin Cardiol 35 2012 730 737
9. G. Lu, F.R. DeGuzman, S.J. Hollenbach, M.J. Karbarz, K. Abe, and G. Lee et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nat Med 19 2013 446 451
10. F. Schiele, J. van Ryn, K. Canada, C. Newsome, E. Sepulveda, and J. Park et al. A specific antidote for dabigatran: functional and structural characterization Blood 121 2013 3554 3562
11. M. Makris, J.J. Van Veen, C.R. Tait, A.D. Mumford, M. Laffan, and British Committee for Standards in Haematology Guideline on the management of bleeding in patients on antithrombotic agents Br J Haematol 160 2013 35 46
12. M. Levi, J.H. Levy, H.F. Andersen, and D. Truloff Safety of recombinant activated factor VII in randomized clinical trials N Engl J Med 363 2010 1791 1800
13. E. Perzborn, A. Gruber, H. Tinel, U.M. Marzec, U. Buetehorn, and A. Buchmueller et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates Thromb Haemost 110 2013 162 172
14. P. Esnault, P.E. Gaillard, J. Cotte, P.J. Cungi, J. Beaume, and B. Prunet Haemodialysis before emergency surgery in a patient treated with dabigatran Br J Anaesth 111 2013 776 777
15. D. Khadzhynov, F. Wagner, S. Formella, E. Wiegert, V. Moschetti, and T. Slowinski et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease Thromb Haemost 109 2013 596 605
16. D.N. Chang, W.E. Dager, and A.I. Chin Removal of dabigatran by hemodialysis Am J Kidney Dis 61 2013 487 489
17. T. Singh, T.T. Maw, B.L. Henry, N.M. Pastor-Soler, M.L. Unruh, and K.R. Hallows et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience Clin J Am Soc Nephrol 8 2013 1533 1539
18. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
19. C.B. Granger, J.H. Alexander, J.J.V. Mc Murray, R.D. Lopes, E.M. Hylek, and M. Hanna et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
20. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
21. R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, and A.S. Gallus et al. Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
22. H.R. Bueller, M.H. Prins, A.W. Lensin, H. Decousus, B.F. Jacobson, and E. Minar et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
23. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, and M. Johnson et al. Oral apixaban for the treatment of acute venous thromboembolism N Engl J Med 369 2013 799 808
24. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
25. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, and M. Johnson et al. Apixaban for extended treatment of venous thromboembolism N Engl J Med 368 2013 699 708
26. S. Schulman, C. Kearon, A.K. Kakkar, S. Schellong, H. Eriksson, and D. Baanstra et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism N Engl J Med 368 2013 709 718
27. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and P. Hornick Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial Lancet 375 2010 807 815
28. M.R. Lassen, A. Gallus, G.E. Raskob, G. Pineo, D. Chen, and L.M. Ramirez Apixaban versus enoxaparin for thromboprophylaxis after hip replacement N Engl J Med 363 2010 2487 2498
29. M.R. Lassen, W. Ageno, L.C. Borris, J.R. Lieberman, N. Rosencher, and T.J. Bandel et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786
30. B.I. Eriksson, O.E. Dahl, M.H. Huo, A.A. Kurth, S. Hantel, and K. Hermansson et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) Thromb Haemost 105 2011 721 729
31. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick et al. Dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185
32. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956
33. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, and A.K. Kakkar et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775
34. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, and J. Muntz et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 2008 31 39
35. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and R.J. Portman Apixaban or enoxaparin for thromboprophylaxis after knee replacement N Engl J Med 361 2009 594 604
36. J.S. Ginsberg, B.L. Davidson, P.C. Comp, C.W. Francis, R.J. Friedman, and M.H. Huo et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery J Arthroplasty 24 2009 1 9
37. A.G. Turpie, M.R. Lassen, B.L. Davidson, K.A. Bauer, M. Gent, and L.M. Kwong et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 2009 1673 1680
38. J.W. Eikelboom, S.J. Connolly, M. Brueckmann, C.B. Granger, A.P. Kappetein, and M.J. Mack et al. Dabigatran versus warfarin in patients with mechanical heart valves N Engl J Med 369 2013 1206 1214
39. S. Kuipers, S.C. Cannegieter, S. Middeldorp, F.R. Rosendaal, and H.R. Büller Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences J Thromb Haemost 4 2006 2373 2376
40. S. Kuipers, S.C. Cannegieter, S. Middeldorp, L. Robyn, H.R. Büller, and F.R. Rosendaal The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations PLoS Med 4 2007 e290
41. WHO. WHO Research Into Global Hazards of Travel (WRIGHT) Project. Final report of phase I. Available at: www.who.int/cardiovascular diseases/wright project. [accessed 10.08.13].
42. S. Kuipers, A.J. Schreijer, S.C. Cannegieter, H.R. Büller, F.R. Rosendaal, and S. Middeldorp Travel and venous thrombosis: a systematic review J Intern Med 262 2007 615 634
43. A.J. Trujillo-Santos, A. Jimenez-Puente, and E. Perea-Milla Association between long travel and venous thromboembolic disease: a systematic review and meta-analysis of case-control studies Ann Hematol 87 2008 79 86
44. D. Chandra, E. Parisini, and D. Mozaffarian Meta-analysis: travel and risk for venous thromboembolism Ann Intern Med 151 2009 180 190
45. S.C. Cannegieter, C.J. Doggen, H.C. van Houwelingen, and F.R. Rosendaal Travel-related venous thrombosis: results from a large population-based case control study (MEGA study) PLoS Med 3 2006 1258 1265
46. M.R. Cesarone, G. Belcaro, A.N. Nicolaides, L. Incandela, M.T. De Sanctis, and G. Geroulakos et al. Venous thrombosis from air travel: the LONFLIT3 study. Prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk-subjects: a randomized trial Angiology 53 2002 1 6
47. G. Belcaro, G. Geroulakos, A. Nicolaides, K.A. Myers, and M. Winford Venous thromboembolism from air travel. The LONFLIT study Angiology 52 2001 369 374
48. T. Schwarz, G. Siegert, W. Oettler, K. Halbritter, J. Beyer, and R. Frommhold et al. Venous thrombosis after long-haul flights Arch Intern Med 163 2003 2759 2764
49. R.J. Hughes, R.J. Hopkins, S. Hill, M. Weatherall, N. Van de Water, and M. Nowitz et al. Venous thromboembolism in low to moderate risk long distance air travellers: the New Zealand Air Traveller's Thrombosis (NZATT) study Lancet 362 2003 2039 2044
50. J. Ringwald, C. Schifferdecker, C. Raemsch, J. Strobel, and R. Eckstein Travelers' thrombosis - a state of practise in Germany J Travel Med 18 2011 44 52
51. T.A. Brighton, J.W. Eikelboom, K. Mann, R. Mister, A. Gallus, and P. Ockelford et al. Low-dose aspirin for preventing recurrent venous thromboembolism N Engl J Med 367 2012 1979 1987
52. C. Becattini, G. Agnelli, A. Schenone, S. Eichinger, E. Bucherini, and M. Silingardi et al. Aspirin for prevent in the recurrence of venous thromboembolism N Engl J Med 366 2012 1959 1967
53. H.G. Watson, and T.P. Baglin Guidelines on travel-related venous thrombosis Br J Haematol 152 2011 31 34
54. German guideline to prophylaxis of venous thromboembolism (VTE) March 2009 AWMF-Register-Nr. 003/001 http://www.uni-duesseldorf.de/AWMF/ll/003-001.htm
55. S.R. Kahn, W. Lim, A.S. Dunn, M. Cushman, F. Dentali, and E.A. Akl et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 e195S e226S
56. W. Schobersberger, W.D. Toff, B. Eklöf, G. Fraedrich, H.C. Gunga, and S. Haas et al. Traveller's thrombosis: international consensus statement VASA 37 2008 311 317
57. W.H. Geerts, D. Bergqvist, G.F. Pineo, J.A. Heit, C.M. Samama, and M.R. Lassen et al. Prevention of venous thromboembolism: American College of Chest physicians evidence-based clinical Practice guidelines (8th edition) Chest 133 6 Suppl. 2008 381S 453S
58. S.Z. Goldhaber, A. Leizorovicz, A.K. Kakkar, S.K. Haas, G. Merli, and R.M. Knabb et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients N Engl J Med 365 2011 2167 2177
59. A.T. Cohen, T.E. Spiro, H.R. Büller, L. Haskell, D. Hu, and R. Hull et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients N Engl J Med 368 2013 513 523